<?xml version='1.0' encoding='utf-8'?>
<document id="24728182"><sentence text="Investigation of combined CYP3A4 inductive/inhibitory properties by studying statin interactions: a model study with the renin inhibitor ACT-178882." /><sentence text="ACT-178882, a direct renin inhibitor, was used as a model compound in an elaborate drug-drug interaction study with atorvastatin and simvastatin to explore complex CYP3A4 inductive and inhibitory properties"><entity charOffset="116-128" id="DDI-PubMed.24728182.s2.e0" text="atorvastatin" /><entity charOffset="133-144" id="DDI-PubMed.24728182.s2.e1" text="simvastatin" /><pair ddi="false" e1="DDI-PubMed.24728182.s2.e0" e2="DDI-PubMed.24728182.s2.e0" /><pair ddi="false" e1="DDI-PubMed.24728182.s2.e0" e2="DDI-PubMed.24728182.s2.e1" /></sentence><sentence text="" /><sentence text="Thirty-two healthy male subjects received single doses of 20 mg atorvastatin and 20 mg simvastatin on days 1, 9, 31, and 41"><entity charOffset="64-76" id="DDI-PubMed.24728182.s4.e0" text="atorvastatin" /><entity charOffset="87-98" id="DDI-PubMed.24728182.s4.e1" text="simvastatin" /><pair ddi="false" e1="DDI-PubMed.24728182.s4.e0" e2="DDI-PubMed.24728182.s4.e0" /><pair ddi="false" e1="DDI-PubMed.24728182.s4.e0" e2="DDI-PubMed.24728182.s4.e1" /></sentence><sentence text=" On days 6 to 33, 500 mg ACT-178882 was administered once daily" /><sentence text=" Plasma concentrations of ACT-178882, simvastatin, and atorvastatin were measured by LC-MS/MS"><entity charOffset="26-36" id="DDI-PubMed.24728182.s6.e0" text="ACT-178882" /><entity charOffset="38-49" id="DDI-PubMed.24728182.s6.e1" text="simvastatin" /><entity charOffset="55-67" id="DDI-PubMed.24728182.s6.e2" text="atorvastatin" /><pair ddi="false" e1="DDI-PubMed.24728182.s6.e0" e2="DDI-PubMed.24728182.s6.e0" /><pair ddi="false" e1="DDI-PubMed.24728182.s6.e0" e2="DDI-PubMed.24728182.s6.e1" /><pair ddi="false" e1="DDI-PubMed.24728182.s6.e0" e2="DDI-PubMed.24728182.s6.e2" /><pair ddi="false" e1="DDI-PubMed.24728182.s6.e1" e2="DDI-PubMed.24728182.s6.e1" /><pair ddi="false" e1="DDI-PubMed.24728182.s6.e1" e2="DDI-PubMed.24728182.s6.e2" /></sentence><sentence text=" Routine safety assessments were performed throughout the study" /><sentence text="" /><sentence text="Exposure (as based on area under the curve) to simvastatin and 6β-hydroxyacid simvastatin increased (90 % confidence interval) 4"><entity charOffset="47-58" id="DDI-PubMed.24728182.s9.e0" text="simvastatin" /><entity charOffset="63-89" id="DDI-PubMed.24728182.s9.e1" text="6β-hydroxyacid simvastatin" /><pair ddi="false" e1="DDI-PubMed.24728182.s9.e0" e2="DDI-PubMed.24728182.s9.e0" /><pair ddi="false" e1="DDI-PubMed.24728182.s9.e0" e2="DDI-PubMed.24728182.s9.e1" /></sentence><sentence text="63-fold (3" /><sentence text="90, 5" /><sentence text="50) and 3" /><sentence text="71-fold (3" /><sentence text="19, 4" /><sentence text="32), respectively, when comparing day 9 and day 1" /><sentence text=" On day 9, exposure to atorvastatin was similar but Cmax decreased, while both variables decreased for ortho-hydroxy atorvastatin when compared to day 1"><entity charOffset="23-35" id="DDI-PubMed.24728182.s16.e0" text="atorvastatin" /><entity charOffset="103-129" id="DDI-PubMed.24728182.s16.e1" text="ortho-hydroxy atorvastatin" /><pair ddi="false" e1="DDI-PubMed.24728182.s16.e0" e2="DDI-PubMed.24728182.s16.e0" /><pair ddi="false" e1="DDI-PubMed.24728182.s16.e0" e2="DDI-PubMed.24728182.s16.e1" /></sentence><sentence text=" On day 31, after prolonged administration of ACT-178882, exposure to atorvastatin, ortho-hydroxy atorvastatin, simvastatin, and 6β-hydroxyacid simvastatin decreased by 14, 19, 21, and 27 %, respectively, when compared to day 9"><entity charOffset="70-82" id="DDI-PubMed.24728182.s17.e0" text="atorvastatin" /><entity charOffset="84-110" id="DDI-PubMed.24728182.s17.e1" text="ortho-hydroxy atorvastatin" /><entity charOffset="112-123" id="DDI-PubMed.24728182.s17.e2" text="simvastatin" /><entity charOffset="129-155" id="DDI-PubMed.24728182.s17.e3" text="6β-hydroxyacid simvastatin" /><pair ddi="false" e1="DDI-PubMed.24728182.s17.e0" e2="DDI-PubMed.24728182.s17.e0" /><pair ddi="false" e1="DDI-PubMed.24728182.s17.e0" e2="DDI-PubMed.24728182.s17.e1" /><pair ddi="false" e1="DDI-PubMed.24728182.s17.e0" e2="DDI-PubMed.24728182.s17.e2" /><pair ddi="false" e1="DDI-PubMed.24728182.s17.e0" e2="DDI-PubMed.24728182.s17.e3" /><pair ddi="false" e1="DDI-PubMed.24728182.s17.e1" e2="DDI-PubMed.24728182.s17.e1" /><pair ddi="false" e1="DDI-PubMed.24728182.s17.e1" e2="DDI-PubMed.24728182.s17.e2" /><pair ddi="false" e1="DDI-PubMed.24728182.s17.e1" e2="DDI-PubMed.24728182.s17.e3" /><pair ddi="false" e1="DDI-PubMed.24728182.s17.e2" e2="DDI-PubMed.24728182.s17.e2" /><pair ddi="false" e1="DDI-PubMed.24728182.s17.e2" e2="DDI-PubMed.24728182.s17.e3" /></sentence><sentence text=" However, on this day, exposure to simvastatin and its metabolite was still markedly higher when compared to day 1"><entity charOffset="35-46" id="DDI-PubMed.24728182.s18.e0" text="simvastatin" /></sentence><sentence text=" Effects of ACT-178882 had largely dissipated on day 41" /><sentence text="" /><sentence text="This design enabled the study of complex time-dependent effects on CYP3A4 activity with clinically relevant substrates" /><sentence text="" /></document>